keyword
MENU ▼
Read by QxMD icon Read
search

hiv regimens

keyword
https://www.readbyqxmd.com/read/29775399/dolutegravir-and-rilpivirine-for-the-maintenance-treatment-of-virologically-suppressed-hiv-1-infection
#1
Jose L Casado, Marta Monsalvo, Aurora M Rojo, María Fontecha, Miguel A Rodriguez-Sagrado
Triple combinations of antiretroviral (ART) drugs are the standard treatment for HIV infection, but the challenges include long-term side effects, high costs, and adherence. The recent advent of potent and well tolerated ART has renewed the interest for newer ART strategies. A dual regimen with the combination of dolutegravir (DTG) and rilpivirine (RPV), two well tolerated, metabolic-friendly, and potent drugs could offer additional benefits. Areas covered: A review of recent randomized trials and observational cohorts concerning the use of a dual therapy with DTG plus RPV as a switching strategy in patients with viral suppression...
May 18, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29773899/management-of-acute-hcv-infection-in-the-era-of-direct-acting-antiviral-therapy
#2
REVIEW
Marianne Martinello, Behzad Hajarizadeh, Jason Grebely, Gregory J Dore, Gail V Matthews
The management of acute HCV infection has not been standardized following the availability of direct-acting antiviral agents (DAAs) for chronic HCV infection, and substantial uncertainty exists regarding the optimal treatment regimen and duration. Despite the lack of direct evidence, the 2016 American Association for the Study of Liver Diseases (AASLD)-Infectious Diseases Society of America (IDSA) guidelines supported "the same regimens for acute HCV as recommended for chronic HCV infection … owing to high efficacy and safety", whereas the 2016 European Association for the Study of the Liver (EASL) guidelines recommended sofosbuvir-ledipasvir, sofosbuvir-velpatasvir or sofosbuvir plus daclatasvir for 8 weeks in acute HCV infection, with a longer duration of 12 weeks recommended for those infected with HIV and/or baseline HCV RNA levels >1,000,000 IU/ml...
May 17, 2018: Nature Reviews. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29773829/sequential-immunizations-with-a-panel-of-hiv-1-env-virus-like-particles-coach-immune-system-to-make-broadly-neutralizing-antibodies
#3
Teena Mohan, Zachary Berman, Sang-Moo Kang, Bao-Zhong Wang
Broadly neutralizing antibodies (bnAbs) are correlated with passive HIV/SHIV protection and are desirable components of a HIV protective immunity. In the current study, we have designed a sequential-immunization strategy with a panel of envelope glycoprotein (Env)-enriched virus-like particles (VLPs) from various HIV-1 clades (A-E) to elicit bnAbs with high breadth and potency of neutralization in rabbits. We have compared this regimen with repetitive immunizations of individual Env (subtype B) VLPs or a mixture of various Env VLPs...
May 17, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29772068/risk-factors-associated-with-preterm-delivery-and-low-delivery-weight-among-hiv-exposed-neonates-in-china
#4
Liming Wang, Hongxin Zhao, Weiping Cai, Jie Tao, Qingxia Zhao, Lijun Sun, Qingbo Fan, Athena P Kourtis, Colin Shepard, Fujie Zhang
OBJECTIVE: To examine the relationship between combination antiretroviral therapy (cART) and preterm delivery (PTD) or low delivery weight among pregnant Chinese women with HIV. METHODS: The present retrospective cross-sectional medical chart review enrolled pregnant women with HIV who delivered at five tertiary hospitals in China between January 1, 2009, and December 31, 2014. Generalized linear mixed modeling was used to explore PTD (<37 weeks of pregnancy) and low delivery weight (<2500 g) risk factors...
May 17, 2018: International Journal of Gynaecology and Obstetrics
https://www.readbyqxmd.com/read/29771789/raltegravir-1200-mg-once-daily-vs-400-mg-twice-daily-with-emtricitabine-and-tenofovir-disoproxil-fumarate-for-previously-untreated-hiv-1-infection-week-96-results-from-oncemrk-a-randomized-double-blind-non-inferiority-trial
#5
Pedro Cahn, Paul E Sax, Kathleen Squires, Jean-Michel Molina, Winai Ratanasuwan, Mohammed Rassool, Mark Bloch, Xia Xu, Yan Zhou, Brenda Homony, Deborah Hepler, Hedy Teppler, George J Hanna, Bach-Yen Nguyen, Wayne Greaves
BACKGROUND: Raltegravir 1200mg (2x600mg tablets) once daily (QD) demonstrated non-inferior efficacy and similar safety to raltegravir 400mg BID at Week 48 of the ONCEMRK trial. Here we report the Week 96 results from this study. METHODS: ONCEMRK is a phase 3, multicenter, double-blind, non-inferiority trial comparing raltegravir 1200mg QD to raltegravir 400mg BID in treatment-naïve HIV-1-infected adults. Participants were assigned (2:1) to raltegravir 2x600mg QD or 400mg BID, both with emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) for 96 weeks...
May 3, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29771694/fostemsavir-a-new-cd4-attachment-inhibitor
#6
Pedro Cahn, Valeria Fink, Patricia Patterson
PURPOSE OF REVIEW: Even in the era of modern HAART, antiretroviral (ARV) failure and emergence of drug resistance is still a problem worldwide. New classes with different mechanisms of action are needed to overcome this challenge. After the integrase inhibitors were launched, more than a decade ago, no new classes were added to the ARV armamentarium. RECENT FINDINGS: Fostemsavir (FTR) is an attachment inhibitor, active regardless of viral tropism, without cross-resistance to any of the existing ARV compounds...
May 15, 2018: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/29770748/the-effect-of-switching-protease-inhibitors-to-raltegravir-on-endothelial-function-in-hiv-infected-patients
#7
Maaike Krikke, Kiki Tesselaar, Guido E L van den Berk, Sigrid A Otto, Laura H Freriks, Steven F L van Lelyveld, Frank J L Visseren, Andy I M Hoepelman, Joop E Arends
Objective Lipid management is one of the cornerstones of cardiovascular risk reduction. Treatment of HIV infection with protease inhibitors (PIs) may cause dyslipidaemia, whilst the integrase inhibitor raltegravir (RAL) has a relatively favorable effect on plasma lipids. We examined the effect of switching from PIs to RAL on endothelial function, and its effect on immunological and inflammatory parameters. Methods We performed a 16-week open-label prospective crossover study: 8 weeks intervention (switch PIs to RAL) and 8 weeks control (unchanged cART regimen)...
April 2018: HIV Clinical Trials
https://www.readbyqxmd.com/read/29769263/how-i-treat-burkitt-lymphoma-in-children-adolescents-and-young-adults-in-sub-saharan-africa
#8
Satish Gopal, Thomas G Gross
Burkitt lymphoma (BL) is the most common pediatric cancer in sub-Saharan Africa (SSA), and also occurs frequently among adolescents and young adults (AYA), often associated with human immunodeficiency virus (HIV). Treating BL in SSA poses particular challenges. Although highly effective, high-intensity cytotoxic treatments used in resource-rich settings are usually not feasible, and lower-intensity continuous infusion approaches are impractical. In this paper, based on evidence from the region, we review management strategies for SSA focused on diagnosis, use of pre-phase, and definitive treatment...
May 16, 2018: Blood
https://www.readbyqxmd.com/read/29767640/burden-of-exposure-to-potential-interactions-between-antiretroviral-and-non-antiretroviral-medications-in-a-population-of-hiv-positive-patients-aged-50-years-or-older
#9
Alice Ranzani, Letizia Oreni, Massimiliano Agrò, Lorena van den Bogaart, Laura Milazzo, Andrea Giacomelli, Dario Cattaneo, Cristina Gervasoni, Anna Lisa Ridolfo
BACKGROUND: As HIV-infected patients aged 50 years or older are at increased risk of comorbidities and multidrug treatments, we examined their exposure to the potential drug-drug interactions (PDDIs) of antiretroviral (ARV) and other medications. METHODS: This cross-sectional study involved the patients aged 50 years or older receiving ARV and non-ARV medications at our clinic. PDDIs were identified using the University of Liverpool HIV Drug Interaction Checker...
June 1, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29767543/efficacy-of-single-tablet-darunavir-cobicistat-emtricitabine-and-tenofovir-alafenamide-in-the-treatment-of-hiv-1
#10
Eugènia Negredo, Bonaventura Clotet
HIV eradication is not feasible and lifelong treatment is warranted to manage HIV infection. In this scenario, the advent of single-tablet, once-daily, fixed-dose co-formulations is important for reducing pill burden and maximize long-term drug adherence. Cobicistat-boosted darunavir along with emtricitabine and tenofovir alafenamide co-formulation (DRV/c/FTC/TAF or the trade name Symtuza®) is the first marketed protease inhibitor-based fixed-dose combination regimen for the treatment of HIV infection. It was approved in late 2017 by the European Medical Agency both for naïve patients and treatment-experienced patients with viral suppression...
May 16, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29766813/coreceptor-tropism-and-maraviroc-sensitivity-of-clonally-derived-ethiopian-hiv-1c-strains-using-an-in-house-phenotypic-assay-and-commonly-used-genotypic-methods
#11
Amare Worku Kalu, Nigus Fikrie Telele, Shambhu Aralaguppe, Solomon Gebre-Selassie, Daniel Fekade, Gaetano Marrone, Anders Sonnerborg
OBJECTIVES: Genotypic tropism testing (GTT) tools are generally developed based on HIV-1 subtype B (HIV-1B) and used for HIV-1C as well but with a large discordance of prediction between different methods. We used an established phenotypic assay for comparison with GTT methods and for determination of in vitro maraviroc sensitivity of pure R5-tropic and dual-tropic HIV-1C. METHODS: Plasma was obtained from 58 HIV-1C infected Ethiopians. Envgp120 was cloned into a luciferase tagged NL4-3 plasmid...
May 15, 2018: Current HIV Research
https://www.readbyqxmd.com/read/29765285/anemia-and-thrombocytopenia-in-the-cohort-of-hiv-infected-adults-in-northwest-ethiopia-a-facility-based-cross-sectional-study
#12
Tekalign Deressa, Debasu Damtie, Meseret Workineh, Meaza Genetu, Mulugeta Melku
Background: Anemia and thrombocytopenia are frequent hematological abnormalities in patients with human immunodeficiency virus (HIV) infection and have been associated with increased morbidity and mortality. However, there is a paucity of data on the prevalence and correlates of these hematological abnormalities among HIV infected adults in Ethiopia. The aim of this study was to determine the prevalence and correlates of anemia and thrombocytopenia in a cohort of HIV-1 infected adults in northwest Ethiopia...
April 2018: EJIFCC
https://www.readbyqxmd.com/read/29765256/grazoprevir-elbasvir-for-the-treatment-of-adults-with-chronic-hepatitis-c-a-short-review-on-the-clinical-evidence-and-place-in-therapy
#13
REVIEW
Nimisha Sulejmani, Syed-Mohammed Jafri
Chronic hepatitis C virus (HCV) infection impacts approximately 71 million people and approximately 400,000 deaths are attributed to HCV-related liver disease annually worldwide. Mainstay of treatment for over 25 years has been pegylated interferon until the advent of protease inhibitors, which has led to all-oral HCV treatment regimens that have changed the outlook of hepatitis C treatment. Grazoprevir/elbasvir provides high rates of efficacy and tolerability and is an all-oral once daily treatment option for HCV infection...
2018: Hepatic Medicine: Evidence and Research
https://www.readbyqxmd.com/read/29762171/hiv-transmission-in-discordant-couples-in-africa-in-the-context-of-art-availability
#14
Evonne Woodson, Alec Goldberg, Clive Michelo, Debby Basu, Sijia Tao, Raymond Schinazi, Yong Jiang, William Kilembe, Etienne Karita, Susan Allen, Eric Hunter
OBJECTIVE: This study aims to understand the basis of continued HIV-1 transmission in Zambian and Rwandan HIV-1 discordant couples in the context of ART. DESIGN: We identified 9 Zambian and 7 Rwandan acutely-infected, epidemiologically-linked couples from government CVCT clinics where transmitting partners reported being on ART near the time of transmission. METHODS: We quantified viral load (VL) and plasma antiretroviral (ARV) drug concentrations near the time of transmission and used these as surrogate measures for adherence...
May 11, 2018: AIDS
https://www.readbyqxmd.com/read/29762169/change-in-sexual-risk-behaviour-after-six-months-of-pre-exposure-prophylaxis-use-results-from-the-amsterdam-prep-demonstration-project
#15
Elske Hoornenborg, Liza Coyer, Anna van Laarhoven, Roel Achterbergh, Henry de Vries, Maria Prins, Maarten Schim van der Loeff
OBJECTIVE: HIV pre-exposure prophylaxis (PrEP) use may lead to higher STI incidence via behavioral risk compensation. We examined changes in sexual behaviour between baseline and six months after PrEP initiation among men who have sex with men (MSM) and transgender women (TGW). DESIGN: Prospective, open-label demonstration study at a large sexually transmitted infections (STI) clinic in Amsterdam, the Netherlands. METHODS: Participants answered questions about sexual behaviour in the preceding three months, including number of anal sex partners and frequency of anal sex with and without condom by partner type and were tested for STI...
May 11, 2018: AIDS
https://www.readbyqxmd.com/read/29762043/the-effects-of-fish-oil-on-hiv-related-inflammation-and-markers-of-immunosenescence-a-randomized-clinical-trial
#16
Barbara Swanson, Joyce Keithley, Linda Baum, Sue Leurgans, Oluwatoyin Adeyemi, Lisa L Barnes, Mariana Mata, Anneliese Rosdil
OBJECTIVE: To explore the safety and efficacy of fish oil to modulate parameters of inflammation and immunosenescence in HIV-infected older adults. DESIGN: This study uses a randomized, controlled, double-blind clinical trial. SETTING: The study was conducted in an outpatient HIV/AIDS clinic in a large urban Midwestern city in the United States. SUBJECTS: A total of 37 clinically stable HIV-infected adults between the ages of 40 and 70 years of age participated...
May 15, 2018: Journal of Alternative and Complementary Medicine: Research on Paradigm, Practice, and Policy
https://www.readbyqxmd.com/read/29761330/a-review-of-long-term-toxicity-of-antiretroviral-treatment-regimens-and-implications-for-an-aging-population
#17
REVIEW
Anita Chawla, Christina Wang, Cody Patton, Miranda Murray, Yogesh Punekar, Annemiek de Ruiter, Corklin Steinhart
Human immunodeficiency virus (HIV) is a chronic infectious disease currently requiring lifelong antiretroviral therapy (ART). People living with HIV (PLWH) face an increased risk of comorbidities associated with aging, chronic HIV, and the toxicity arising from long-term ART. A literature review was conducted to identify the most recent evidence documenting toxicities associated with long-term ART, particularly among aging PLWH. In general, PLWH are at a greater risk of developing fractures, osteoporosis, renal and metabolic disorders, central nervous system disorders, cardiovascular disease, and liver disease...
May 14, 2018: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/29760693/treatment-intensification-in-hiv-infected-patients-is-associated-with-reduced-frequencies-of-regulatory-t-cells
#18
Eva M Grützner, Tanja Hoffmann, Eva Wolf, Elke Gersbacher, Ashley Neizert, Renate Stirner, Ramona Pauli, Albrecht Ulmer, Jürgen Brust, Johannes R Bogner, Hans Jaeger, Rika Draenert
In untreated HIV infection, the efficacy of T cell responses decreases over the disease course, resulting in disease progression. The reasons for this development are not completely understood. However, immunosuppressive cells are supposedly crucially involved. Treatment strategies to avoid the induction of these cells preserve immune functions and are therefore the object of intense research efforts. In this study, we assessed the effect of treatment intensification [=5-drug antiretroviral therapy (ART)] on the development of suppressive cell subsets...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29760133/pharmacokinetics-and-safety-profile-of-artesunate-amodiaquine-co-administered-with-antiretroviral-therapy-in-malaria-uninfected-hiv-positive-malawian-adults
#19
Clifford G Banda, Fraction Dzinjalamala, Mavuto Mukaka, Jane Mallewa, Victor Maiden, Dianne J Terlouw, David G Lalloo, Saye H Khoo, Victor Mwapasa
There are limited data on the pharmacokinetic and safety profiles of artesunate-amodiaquine in human immnunodeficiency virus infected (HIV+) individuals receiving antiretroviral therapy. In a two-step intensive sampling pharmacokinetic trial, we compared area under the concentration-time curve from 0 to 28 days (AUC0-28 days ) of an active metabolite of amodiaquine, desethylamodiaquine, and treatment-emergent adverse events between antiretroviral therapy-naive HIV+ adults and those taking nevirapine and ritonavir-boosted lopinavir-based antiretroviral therapy...
May 14, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29759422/executive-summary-of-the-gesida-national-aids-plan-consensus-document-on-antiretroviral-therapy-in-adults-infected-by-the-human-immunodeficiency-virus-updated-january-2018
#20
(no author information available yet)
This update to the document on antiretroviral therapy (ART) in adults, which has been prepared jointly by GeSIDA and the Spanish National AIDS Plan for the last two decades, supersedes the document published in 2017.1 The update provides physicians treating HIV-1-infected adults with evidence-based recommendations to guide their therapeutic decisions. The main difference with respect to the previous document concerns recommended initial ART regimens, only three of which are maintained as preferential. All three include dolutegravir or raltegravir, together with emtricitabine/tenofovir alafenamide or abacavir/lamivudine...
May 11, 2018: Enfermedades Infecciosas y Microbiología Clínica
keyword
keyword
111310
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"